In discussion with Dr. Jens Hillengasss from Roswell Park Comprehensive Cancer Center, covering the Multiple Myeloma key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Hillengass:

PERSEUS – Ph 3 Randomized Study of Dara + Bortezomib + Len + Dex (DaraVRd) vs VRd Alone in Patients with NDMM Who Are Eligible for Autologous Stem Cell Transplantation (ASCT)

IsKia – Ph 3 Randomized Study of IsatuximabCarfilzomibLenalidomideDexamethasone vs CarfilzomibLenalidomideDexamethasone As PreTransplant Induction and PostTransplant Consolidation in NDMM

Bortezomib Dosing Retrospective Observational Study on RealWorld Bortezomib Prescribing Patterns and Outcomes in NDMM

KarMMA3 Update Idecabtagene Vicleucel (idecel) vs Standard Regimens in Patients with TripleClass–Exposed (TCE) RRMM: Updated Analysis

#ASH #CART #Myeloma #MultipleMyeloma #Cancer #2023 #oncology #oncbrothers

Website: http://www.oncbrothers.com/

Twitter:   / oncbrothers  

Contact us at [email protected]